SAVIMS

SAVIMS logo white
Menu

Resource Type

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Analysis of Mis-categorisation in Covid-19 Mortality Data

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Neil, M., Fenton, N., Smalley, J., Craig, C., Guetzkow, J., McLachlan, S., Engler, J., & Rose, J. (2021). Latest statistics on England mortality data suggest systematic mis-categorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination. ResearchGate. https://doi.org/10.13140/RG.2.2.14176.20483 Summary: This article scrutinises England’s Covid-19 mortality data, revealing potential systematic mis-categorisation of vaccination status. While […]

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Long-term Persistence of SARS-CoV-2 Spike Protein: Implications for Vaccination

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Palmer, M., & Bhakdi, S. (2021). Long-term persistence of the SARS-CoV-2 spike protein: Evidence and implications. doctors4covidethics.org. Summary: The article by Palmer and Bhakdi examines a study by Bansal et al. that identified the presence of SARS-CoV-2 spike protein in exosomes for up to four months post-vaccination with the Pfizer mRNA vaccine. This prolonged

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Long-term Persistence of SARS-CoV-2 Spike Protein: Implications for Health

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Palmer, M., & Bhakdi, S. (2021). Long-term persistence of the SARS-CoV-2 spike protein: Evidence and implications. doctors4covidethics.org. Summary: The article by Palmer and Bhakdi discusses a study by Bansal et al. that reveals the prolonged presence of the SARS-CoV-2 spike protein in individuals vaccinated with the Pfizer mRNA vaccine. It highlights that the spike

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Increasing Epidemiological Relevance of Vaccinated Individuals in COVID-19 Transmission

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Kampf, G. (2021). The epidemiological relevance of the COVID-19-vaccinated population is increasing. The Lancet Regional Health – Europe, 11, 100272. https://doi.org/10.1016/j.lanepe.2021.100272 Summary: High COVID-19 vaccination rates were anticipated to diminish SARS-CoV-2 transmission; however, recent findings suggest the opposite. In the UK, secondary attack rates among household contacts exposed to fully vaccinated individuals were similar

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Understanding RRR and ARR in Vaccine Trials

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Iriarte, I., & Phoenix, S. (2021). Understanding relative risk reduction (RRR) and absolute risk reduction (ARR) in vaccine trials. PANDA. https://www.pandata.org/understanding-relative-risk-reduction-and-absolute-risk-reduction-in-vaccine-trials/ Summary: The article discusses the critical distinctions between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) in the context of vaccine trials, particularly those for COVID-19. RRR compares the efficacy of one

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Detection of Graphene in COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Campra, P. (2021). Detection of graphene in COVID-19 vaccines by micro-Raman spectroscopy. Technical Report. Almeria, Spain: Universidad de Almería. Summary: This technical report by Professor Pablo Campra investigates the presence of graphene in various COVID-19 vaccine samples using a technique called micro-Raman spectroscopy. The study screened seven vials from four different vaccine brands, identifying

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of BNT162b2 mRNA Covid-19 Vaccine at 6 Months

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The BNT162b2 mRNA vaccine demonstrates high efficacy and safety against Covid-19,

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162b2 mRNA Covid-19 Vaccine through 6 Months

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The article investigates the safety and efficacy of the BNT162b2 mRNA Covid-19

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Updated COVID-19 Adverse Events Following Immunisation

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: CEPI. (2022, October). COVID-19 AESI including status of associated Brighton case definitions. Retrieved from [insert URL here] Summary: The document presents an updated list of Adverse Events Following Immunisation (AESI) related to COVID-19, alongside their Brighton case definitions. It categorises various conditions such as acute respiratory distress syndrome, myocarditis, and thrombosis, indicating their publication

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19 Associated Events of Special Interest: A Comprehensive Overview

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: CEPI. (2021). COVID-19 associated events of special interest including status of associated Brighton case definitions. Retrieved from https://docs.google.com/spreadsheets/d/1QgF35nYcsaFN3DZTOtV_lP0TYqQzsDMUQBAd5M9brrM/edit#gid=1666959512 Summary: This document provides an overview of COVID-19 associated events of special interest (AESI) alongside their Brighton case definitions as of October 2021. It categorises AESIs into three groups: those seen with COVID-19 disease, those with

Scroll to Top